Latest News
EMA issues positive CHMP opinion for Revolution Medicines' RASONQUE in metastatic pancreatic cancer
15 October 2026 - US-based oncology company Revolution Medicines, Inc. (NASDAQ: RVMD) on Thursday said it has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for RASONQUE (daraxonra...
Edesa Biotech receives FDA clearance to expand EB06 vitiligo study into the US
15 October 2026 - Canadian clinical-stage biopharmaceutical company Edesa Biotech, Inc. (NASDAQ: EDSA) said on Thursday it has received US FDA clearance for its Investigational New Drug application for EB06 in vitiligo.The approval allows the company...
LTR Pharma launches Roxus nasal spray for ED in the US
15 October 2026 - Australian pharmaceutical company LTR Pharma Limited (ASX: LTP) on Thursday introduced Roxus, a prescription nasal spray for erectile dysfunction (ED), to patients across the United States.The product delivers vardenafil via the com...
Galderma reports sustained symptom improvements with nemolizumab in children with atopic dermatitis
15 October 2026 - Dermatology company Galderma (SIX:GALD) on Thursday announced Phase II study results showing that nemolizumab improved itch severity, sleep disturbance and quality of life in children aged 2 to 11 with moderate-to-severe atopic derm...
KDventures portfolio company Modus Therapeutics pauses Phase 2a trial enrolment, delays expected readout
15 October 2026 - KDventures AB (STO:KDV), a Nordic investment company focused on life sciences, disclosed on Thursday that portfolio company Modus Therapeutics has temporarily paused enrolment in Part 2 of its Phase 2a study evaluating sevuparin in ...